Repositorio Dspace

Clinical Outcomes of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People Living With HIV and Low-Level Viraemia

Mostrar el registro sencillo del ítem

dc.contributor.author de-los-Santos, Ignacio
dc.contributor.author Pousada, Guillermo
dc.contributor.author Galera-Peñaranda, Carlos
dc.contributor.author Duenas, Carlos
dc.contributor.author Buzon, Luis
dc.contributor.author Sanz, José
dc.contributor.author Martin, Cristina
dc.contributor.author Garcinuno, María-Ángeles
dc.contributor.author Galindo, María-José
dc.contributor.author García-Fraile, Lucio
dc.contributor.author Pedrero-Tome, Roberto
dc.contributor.author Troya, Jesús
dc.date.accessioned 2026-11-11T09:05:36Z
dc.date.available 2026-11-11T09:05:36Z
dc.date.issued 2026-01
dc.identifier.citation De Los Santos I, Pousada G, Galera C, Dueñas C, Buzón L, Sanz J, et al. Clinical Outcomes of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People Living With HIV and Low-Level Viraemia. J Int Assoc Provid AIDS Care. enero de 2026;25:23259582261482031. doi:10.1177/23259582261482031
dc.identifier.issn 2325-9574
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/29179
dc.description.abstract IntroductionLow-level viraemia (LLV) in people living with HIV (PLWH) remains a clinical challenge, associated with increased risk of virological failure, immune dysregulation, and chronic inflammation. Bictegravir/emtricitabine/tenofovir alafenamide is a single-tablet regimen with a high genetic barrier to resistance, but real-world outcomes after switching in PLWH with LLV remain insufficiently characterized. This study aimed to describe virological, immunological, metabolic, and safety outcomes after switching to bictegravir/emtricitabine/tenofovir alafenamide in PLWH with documented LLV over 96 weeks.MethodsA retrospective, multicentre study was conducted across 12 Spanish healthcare centres. PLWH aged ?18 years with a documented qualifying LLV episode before switch (two consecutive HIV-1 RNA measurements between 50 and 400 copies/mL) who switched to bictegravir/emtricitabine/tenofovir alafenamide were included (N = 123). Outcomes included virological suppression (<50 copies/mL), residual LLV, CD4+/CD8+ dynamics, metabolic changes, and safety. Analyses were descriptive, used observed denominators, and included a non-completer=failure sensitivity analysis for virological suppression.ResultsAmong participants (median age: 52 years, 80.5% male; median time since HIV diagnosis: 30 years), observed LLV decreased to 11.4% (13/114 patients) at 96 weeks after switching to bictegravir/emtricitabine/tenofovir alafenamide (p<0.001). In the non-completer=failure sensitivity analysis, virological suppression at week 96 was 82.1% (101/123). At week 96, all detectable HIV-1 RNA values were 55-272 copies/mL; 3/13 patients had LLV at all available 24-, 48-, and 96-week visits. CD4+/CD8+ ratios remained stable, with a significant reduction in CD8+ T cell counts in patients ?50 years. Biochemical markers were broadly stable, but weight/BMI increases and a shift toward overweight were observed and warrant monitoring. No treatment discontinuations due to adverse events were reported.ConclusionIn this single-arm retrospective cohort, switching to bictegravir/emtricitabine/tenofovir alafenamide was associated with a high observed proportion of virological suppression, immune stability, and favourable tolerability over 96 weeks; however, causal effectiveness cannot be inferred. These findings support further comparative prospective evaluation of bictegravir/emtricitabine/tenofovir alafenamide for LLV management.
dc.language.iso eng
dc.publisher SAGE PUBLICATIONS INC
dc.rights Atribución/Reconocimiento-NoComercial 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by-nc/4.0/deed.es *
dc.subject.mesh Adult
dc.subject.mesh Female
dc.subject.mesh Humans
dc.subject.mesh Male
dc.subject.mesh Middle Aged
dc.subject.mesh Adenine/analogs & derivatives/therapeutic use
dc.subject.mesh Alanine
dc.subject.mesh Amides
dc.subject.mesh Anti-HIV Agents/therapeutic use
dc.subject.mesh CD4 Lymphocyte Count
dc.subject.mesh Drug Substitution
dc.subject.mesh Emtricitabine/therapeutic use
dc.subject.mesh Heterocyclic Compounds, 4 or More Rings/therapeutic use
dc.subject.mesh HIV Infections/drug therapy/virology
dc.subject.mesh HIV-1/drug effects
dc.subject.mesh Pyridones/therapeutic use
dc.subject.mesh Retrospective Studies
dc.subject.mesh Spain
dc.subject.mesh Tenofovir/therapeutic use/analogs & derivatives
dc.subject.mesh Treatment Outcome
dc.subject.mesh Viral Load
dc.subject.mesh Viremia/drug therapy
dc.subject.mesh Heterocyclic Compounds, 3-Ring
dc.subject.mesh Piperazines
dc.title Clinical Outcomes of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People Living With HIV and Low-Level Viraemia
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 42874079
dc.relation.publisherversion https://journals.sagepub.com/doi/10.1177/23259582261482031
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1177/23259582261482031
dc.journal.title Journal of the International Association of Providers of Aids Care
dc.identifier.essn 2325-9582


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta